European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, přehledy
PubMed
35623961
DOI
10.1016/j.ejca.2022.04.018
PII: S0959-8049(22)00228-3
Knihovny.cz E-zdroje
- Klíčová slova
- Adjuvant treatment, Cutaneous melanoma, Excisional margins, Interferon-α, Metastasectomy, Sentinel lymph node dissection, Systemic treatment, Tumor thickness,
- MeSH
- konsensus MeSH
- lidé MeSH
- maligní melanom kůže MeSH
- melanom * patologie MeSH
- mutace MeSH
- nádory kůže * genetika MeSH
- oximy MeSH
- protokoly protinádorové kombinované chemoterapie MeSH
- protoonkogenní proteiny B-Raf genetika MeSH
- staging nádorů MeSH
- systematický přehled jako téma MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
- Názvy látek
- oximy MeSH
- protoonkogenní proteiny B-Raf MeSH
A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("tumor board"). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600 E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.
1st Department of Dermatology Aristotle University Thessaloniki Greece
Center for Dermatooncology Department of Dermatology Eberhard Karls University Tuebingen Germany
Department of Dermatology Erasme Hospital Université Libre de Bruxelles Brussels Belgium
Department of Dermatology Maastricht University Medical Center Maastricht Netherlands
Department of Dermatology Medical University of Vienna Austria
Department of Dermatology University Hospital Schleswig Holstein Campus Kiel Kiel Germany
Department of Dermatovenereology 3rd Faculty of Medicine Charles University Prague Czech Republic
Department of Oncology Odense University Hospital Odense Denmark
Dermatology Clinic Maggiore Hospital University of Trieste Trieste Italy
Dermatology Department CHU Nantes CIC 1413 CRCINA University Nantes Nantes France
Dermatology Unit University of Modena and Reggio Emilia Modena Italy
Medical and Surgical Dermatology Service Hospital Universitario Virgen Macarena Sevilla Spain
Melanoma Unit Department of Dermatology Hospital Clinic IDIBAPS Barcelona Spain
Mount Vernon Cancer Centre Northwood United Kingdom
Shupyk National Medical Academy of Postgraduate Education Kiev Ukraine
The University of Manchester Oxford Rd Manchester M13 9PL United Kingdom
Université Paris Cite AP HP Department of Dermatology INSERM U 976 Hôpital Saint Louis Paris France
Citace poskytuje Crossref.org